West Pharmaceutical Services reported $3.33B of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.33B (to Q2 2026). Net income: $565M, trailing twelve months to Q2 2026. Free cash flow: $437M, trailing twelve months to Q2 2026. Operating margin: 20%, trailing twelve months to Q2 2026.

WSTWest Pharmaceutical Services

Healthcare

$366.17+44% 1Y

$366.17

$230.7852 weeks$376.78

WST as reported

West Pharmaceutical Services reported $3.33B of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed.

$3.33B

Revenue, trailing twelve months · to Q2 2026 · +12% against the twelve months before

Net income: $565M
Net income · +16% year on year · trailing twelve months to Q2 2026
Free cash flow: $437M
Free cash flow · +27% year on year · trailing twelve months to Q2 2026
Operating margin: 20%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for WST, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.33B	+12%	Q2 2026
Net income	$565M	+16%	Q2 2026
EPS	$7.81	+17%	Q2 2026
Gross margin	37%	n/a	Q2 2026
Operating margin	20%	n/a	Q2 2026
Net margin	17%	n/a	Q2 2026
ROE	17%	n/a	Q2 2026
ROA	13%	n/a	Q2 2026
ROIC	19%	n/a	Q2 2026
Free cash flow	$437M	+27%	Q2 2026
P/E	46.9	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.